Key Takeaways
- • Altas Partners and L Catterton have agreed to acquire a majority stake in Fullscript from HGGC and Snapdragon Capital Partners, according to company and sponsor announcements covered by Healthcare IT Today and The Middle Market.
- • Terms of the transaction were not disclosed, and closing is expected in the fourth quarter, subject to customary approvals.
- • Fullscript operates a digital platform that helps healthcare practitioners recommend and dispense supplements and wellness products, sitting at the intersection of healthcare software, practitioner workflow and consumer health purchasing.
- • Centerview Partners advised Fullscript, while Evercore, Morgan Stanley and RBC Capital Markets advised the buyers, a banker slate consistent with a competitive sponsor-to-sponsor process.
- • The deal is a sponsor-to-sponsor exit for HGGC and Snapdragon and signals continued private-market demand for digital health platforms with sticky practitioner relationships.
Summary
Altas Partners and L Catterton have agreed to acquire a majority stake in Fullscript from HGGC and Snapdragon Capital Partners, according to company and sponsor announcements covered by Healthcare IT Today and The Middle Market. Terms were not disclosed, and the transaction is expected to close in the fourth quarter, subject to customary approvals.
Fullscript operates a digital platform that helps healthcare practitioners recommend and dispense supplements and related wellness products. The business sits at the overlap of healthcare software, practitioner workflow and consumer health purchasing, a combination that has attracted both healthcare-focused and consumer private equity capital.
Centerview Partners advised Fullscript, with Evercore, Morgan Stanley and RBC Capital Markets advising the buyers, according to deal coverage. The banker lineup is consistent with a competitive process for a scaled health-tech asset changing hands between financial sponsors.
For HGGC and Snapdragon, the sale represents a sponsor-to-sponsor exit in practitioner-facing health software. For Altas and L Catterton, the majority stake offers a platform that can be expanded through additional practitioner adoption, broader product offerings and potential add-on acquisitions in adjacent wellness and clinical workflow tools. Allocators will watch whether the new owners prioritize clinical channel expansion or consumer brand leverage.
With pricing undisclosed and closing still ahead, the transaction is best read as another data point that digital health platforms with sticky practitioner relationships continue to attract capital in private markets, even as public health-tech multiples have been uneven.
Fullscript operates a digital platform that helps healthcare practitioners recommend and dispense supplements and related wellness products. The business sits at the overlap of healthcare software, practitioner workflow and consumer health purchasing, a combination that has attracted both healthcare-focused and consumer private equity capital.
Centerview Partners advised Fullscript, with Evercore, Morgan Stanley and RBC Capital Markets advising the buyers, according to deal coverage. The banker lineup is consistent with a competitive process for a scaled health-tech asset changing hands between financial sponsors.
For HGGC and Snapdragon, the sale represents a sponsor-to-sponsor exit in practitioner-facing health software. For Altas and L Catterton, the majority stake offers a platform that can be expanded through additional practitioner adoption, broader product offerings and potential add-on acquisitions in adjacent wellness and clinical workflow tools. Allocators will watch whether the new owners prioritize clinical channel expansion or consumer brand leverage.
With pricing undisclosed and closing still ahead, the transaction is best read as another data point that digital health platforms with sticky practitioner relationships continue to attract capital in private markets, even as public health-tech multiples have been uneven.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.